A phase Ib study of the FGFR/VEGFR inhibitor dovitinib with gemcitabine and capecitabine in advanced solid tumor and pancreatic cancer patients

OBJECTIVES: Preclinical studies demonstrated antitumor activity of dovitinib in pancreatic cancer models. This phase Ib study aimed to determine the maximum tolerated dose of dovitinib in combination with gemcitabine and capecitabine and to characterize the safety and pharmacokinetic profile in pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Clin Oncol
Main Authors: Ma, Wen Wee, Xie, Hao, Fetterly, Gerald, Pitzonka, Laura, Whitworth, Amy, LeVea, Charles, Wilton, John, Mantione, Krystin, Schihl, Sarah, Dy, Grace K, Boland, Patrick, Iyer, Renuka, Tan, Wei, Brady, William, Straubinger, Robert M, Adjei, Alex A
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6345595/
https://ncbi.nlm.nih.gov/pubmed/30418178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000492
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados